Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.

The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.

Of the hundreds of exchange-traded funds on the market, some are bound to fail. Learn how to pick the best of the bunch.

Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

Biotechnology-themed exchange-traded funds surged higher late Monday morning as investors rewarded pharmaceutical companies that looked likely to profit from treatments for COVID-19. The SPDR S&P Biotech ETF was up 3.1%, and the iShares NASDAQ Biotechnology ETF gained more than 2%. Two funds with the most exposure to the company making headlines in the morning, Moderna Inc. , jumped even higher: the Loncar Cancer Immunotherapy ETF , with a 13% allocation to Moderna, was 4.8% higher, and the iShares Genomics Immunology and Healthcare ETF was 5% higher. In the year to date, XBI has gained 11.7%, compared with a 8.8% decline for the S&P 500 in that period.

Can biotech ETFs repeat its success story of 2019 in the election year of 2020?

The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.

Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.

Like punk rock, alpha is very much alive.

Biotechnology company Amgen (AMGN) is throwing $2.7 billion into BeiGene (BGNE), sending the Chinese biotech's shares surging and bolstering sector-related ETFs. CNCR was also testing its long-term resistance at the 200-day simple moving average. Amgen announced it was investing $2.7 billion into BeiGene, and the Chinese firm will begin commercializing some of Amgen's cancer drugs to be sold in Chinese markets, CNBC reports.

Healthcare bounced back with an outperformance starting the fourth quarter.

We highlight five biotech ETFs and stocks that are leading the market in Q4.

Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference

Biotech ETFs are among the most popular investment vehicles. Here are some reasons for why they're worth considering.